Division of Nephrology, Department of Internal Medicine, Kaohsiung Veterans' General Hospital, Kaohsiung, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Department of Applied Mathematics, National Sun Yat-sen University, Taiwan.
J Formos Med Assoc. 2021 Jan;120(1 Pt 3):629-640. doi: 10.1016/j.jfma.2020.07.020. Epub 2020 Jul 21.
BACKGROUND/PURPOSE: Prophylactic hemodialysis after coronary angiography in patients with chronic kidney disease (CKD) prevents contrast nephropathy; however, the one-year outcomes are unclear. This study aimed to investigate the one-year outcomes of prophylactic hemodialysis against standard treatment in patients with CKD who underwent coronary angiography.
A cohort study of 359 patients with CKD, coronary artery disease (CAD), and serum creatinine levels of 176.8-530.4 μmol/L, who were referred for elective coronary angiography was conducted. Propensity score matching identified 118 patient pairs for outcome comparisons. The hemodialysis group underwent prophylactic hemodialysis after coronary angiography, whereas the control group received standard treatment. The study's primary outcome was free from dialysis was considered the primary outcome, whereas the secondary outcome was overall survival. Unadjusted estimates of the probability of free from dialysis and overall survival were computed using Kaplan-Meier survival curves and log-rank tests. Cox proportional-hazards regression models were used in determining the risk factors associated with ESRD and mortality.
During a mean 9.3 months follow-up duration, the hemodialysis group had significantly better free from dialysis (85.6% vs. 64.4%; P = 0.002) and overall survival (85.4% vs. 78.5%; P = 0.008) rates than the control group. Cox proportional-hazards regression analyses of the propensity score-matched patients showed that the hemodialysis group had reduced risks for ESRD and mortality (hazard ratios, 0.32 and 0.48, respectively).
Prophylactic Hemodialysis following coronary angiography was associated with reduced ESRD and mortality risks in CKD patients with CAD, who did not routinely undergo dialysis.
背景/目的:在慢性肾脏病(CKD)患者行冠状动脉造影术后进行预防性血液透析可预防对比剂肾病;然而,其一年的预后尚不清楚。本研究旨在探讨在接受冠状动脉造影术的 CKD 患者中,预防性血液透析对比标准治疗的一年预后。
对 359 例 CKD、冠心病(CAD)和血清肌酐水平为 176.8-530.4μmol/L 的患者进行了一项队列研究,这些患者被推荐进行选择性冠状动脉造影术。采用倾向评分匹配法对 118 对患者进行了结果比较。血液透析组在冠状动脉造影术后行预防性血液透析,对照组则接受标准治疗。该研究的主要终点是无透析,次要终点是总生存。采用 Kaplan-Meier 生存曲线和对数秩检验计算无透析和总生存的未调整概率估计值。采用 Cox 比例风险回归模型确定与 ESRD 和死亡率相关的风险因素。
在平均 9.3 个月的随访期间,血液透析组无透析(85.6%比 64.4%;P=0.002)和总生存(85.4%比 78.5%;P=0.008)率显著高于对照组。对倾向评分匹配患者的 Cox 比例风险回归分析显示,血液透析组的 ESRD 和死亡率风险降低(风险比分别为 0.32 和 0.48)。
在未常规进行透析的 CAD 合并 CKD 患者中,冠状动脉造影术后进行预防性血液透析可降低 ESRD 和死亡率风险。